1Disease Modifying Therapy (DMT) in Alzheimer’s Disease comes with risks. Please refer to the specific DMT's prescribing information for side effects, contraindications, and risks
2Faktenzentrale: Demenz, DZNE, https://www.dzne.de/aktuelles/hintergrund/faktenzentrale/ 2024 Alzheimer’s Disease Facts and Figures, Alzheimer’s Association Cancer Today, International Agency for Research on Cancer, WHO
3Data on file.
4T1 contrast can also be acquired using gradient echo based imaging.
5Data courtesy of Wentworth-Douglas Hospital, Dover, New Hampshire, USA.
6syngo.via can be used as a stand-alone device or together with a variety of syngo.via-based software options, which are medical devices on their own right. syngo.via and the syngo.via-based software options are not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details
7AI-Rad Companion Brain MR is not commercially available in all countries, and its future availability cannot be ensured
8Data courtesy of Lausanne University Hospital, Switzerland
9Courtesy of Northwell Health, USA.
10J. Cummings et al. Lecanemab: “Appropriate Use Recommendations.” The Journal of Prevention of Alzheimer’s Disease 2023. https://doi.org/10.14283/jpad.2023.30 https://www.fda.gov/drugs/drug-safety-andavailability/fda-recommend-additional-earlier-mrimonitoring-patients-alzheimers-disease-takingleqembi-lecanemab G.D. Rabinovici et al. Donanemab: “Appropriate use recommendations.” The Journal of Prevention of Alzheimer’s Disease 2025. https://doi.org/10.1016/j.tjpad.2025.100150